JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thron, C. D.
Right arrow Articles by Waud, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thron, C. D.
Right arrow Articles by Waud, D. R.
Journal of Pharmacology And Experimental Therapeutics, Vol. 160, Issue 1, 91-105, 1968
Copyright © 1968 by American Society for Pharmacology and Experimental Therapeutics


THE RATE OF ACTION OF ATROPINE

C. D. Thron 1 and D. R. Waud 1

1 Departments of Pharmacology, State University of New York, Downstate Medical Center, Brooklyn, New York, and Harvard Medical School, Boston, Massachusetts

The rate of action of atropine has been studied in isolated guinea-pig atria, perfused hearts (Langendorff) and longitudinal muscle strips from the guinea-pig ileum. Evidence for a relatively rapid atropine-receptor reaction was obtained by direct observation of hearts perfused at high perfusion pressures, and also from the action of fast-acting antagonists in the presence of atropine in atria and ileum, and from the acceleration of the effect of atropine by pretreatment with dibenamine. In view of this evidence, it appears that the rate of action of atropine in isolated atrium and ileum (or longitudinal muscle strips) is limited by the rate of access of atropine to the receptor region, and not by the rate of the atropine-receptor reaction. The evidence in the literature appearing to support the opposite view is discussed, and it is argued that an access-limited model may be found to explain all the facts. In particular, the affinity of a drug for the muscarinic receptor will be the factor governing its rate of action. The precise roles of such factors as pacemaker shifts, special diffusion barriers and various drug-binding sites other than receptors have not yet been worked out.

Submitted on April 24, 1967
Accepted on November 17, 1967







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1968 by the American Society for Pharmacology and Experimental Therapeutics.